Global Lung Initiative as diagnostic criteria in Asthma-COPD overlap syndrome. Prevalence and characterization of the syndrome in a real-life asthma cohort
2023; ESMON Publicidad; Volume: 34; Issue: 3 Linguagem: Inglês
10.18176/jiaci.0966
ISSN1698-0808
AutoresDiana Betancor, M.P. Oliván Otal, J M Olaguibel, J M Rodrigo-Muñoz, M.J. Álvarez Puebla, E Arismendi, Pilar Barranco, Blanca Barroso, I Bobolea, B Cárdaba, María Jesús Cruz, Elena Curto, V Del Pozo, J Domínguez-Ortega, F J González-Barcala, J A Luna-Porta, C Martínez-Rivera, J Mullol, Xavier Muñoz, C Picado, V Plaza, S Quirce, Manuel J. Rial, Iria Roibás-Veiga, L Soto-Retes, A. Valero, Marcela Valverde-Monge, J Sastre,
Tópico(s)Respiratory Support and Mechanisms
ResumoMethods:Asthma was diagnosed based on the GEMA guidelines and included a postBD FEV1>12% and 200ml on spirometry and/or methacholine PC20<16 mg/ml.Study data included demographic and clinical characteristics, asthma treatment, asthma severity (following GINA guidelines) [1] and control (assessed using the Asthma Control Test (ACT)) and the number and severity of exacerbations.Lung function tests (spirometry, methacholine, and plethysmography), sputum analysis, peripheral blood eosinophilia (PBE) and fractional exhaled nitric oxide (FeNO) were also collected.A full description of the MEGA cohort has been published previously [13].The ethics committees of each participating hospital approved this study.All subjects provided signed informed consent.Quantitative variables were described as mean and standard deviation, and qualitative variables by absolute and relative frequencies.Inter-group comparisons were performed using the chi-square test or Fisher's exact test for qualitative variables and the ANOVA or Kruskal-Wallis test for quantitative variables.The agreement percentage was used to calculate the agreement between both diagnosis criteria.Statistical analysis was carried out using GraphPadInstat6 (GraphPadSoftware Inc, San Diego, CA).P-values <0.05 were considered significant. Limitations:A large proportion of patients from the MEGA cohort, 57.4%, have not undergone post-bronchodilation spirometry, or there is no clinical data about them.As a result, they were excluded from the study.As the methacholine challenge was an inclusion criterion, postBD spirometry was not performed in all patients.Moreover, adequate sputum was obtained from a small sample of patients, just 12.5% from the ACO group and 32.8% from non-ACO.Therefore, the sputum inflammatory profile results could not represent all the studied patients.
Referência(s)